Clinical Trial Update: A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy of donidalorsen (IONIS-PKK-LRx/ISIS 721744) in hereditary angioedema has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Donidalorsen (antisense oligonucleotide targeting prekallikrein)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Hereditary Angioedema | Phase 2 | Status: COMPLETED | Results posted: 2022-09-28